VANDA PHARMACEUTICALS ANNOUNCES NOTICE OF OPPORTUNITY FOR AN FDA HEARING ON THE sNDA FOR HETLIOZ® IN JET LAG DISORDER ...Middle East

PR Newswire - News
VANDA PHARMACEUTICALS ANNOUNCES NOTICE OF OPPORTUNITY FOR AN FDA HEARING ON THE sNDA FOR HETLIOZ® IN JET LAG DISORDER
WASHINGTON, Sept. 7, 2022 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the notice of opportunity for an FDA hearing on Vanda's Supplemental New Drug Application (sNDA) for HETLIOZ® (tasimelteon) to treat jet lag disorder. On August 19, 2019, Vanda...

Hence then, the article about vanda pharmaceuticals announces notice of opportunity for an fda hearing on the snda for hetlioz in jet lag disorder was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( VANDA PHARMACEUTICALS ANNOUNCES NOTICE OF OPPORTUNITY FOR AN FDA HEARING ON THE sNDA FOR HETLIOZ® IN JET LAG DISORDER )

Apple Storegoogle play

Last updated :

Also on site :

Most viewed in News